Construction of A Nomogram Prediction Model for PD-L1 Expression in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters
L Hao, L Wang, M Zhang, J Yan… - Zhongguo fei ai za zhi …, 2023 - europepmc.org
In recent years, immunotherapy represented by programmed cell death 1 (PD-
1)/programmed cell death ligand 1 (PD-L1) immunosuppressants has greatly changed the …
1)/programmed cell death ligand 1 (PD-L1) immunosuppressants has greatly changed the …
Construction of A Nomogram Prediction Model for PD-L1 Expression in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters.
HAO Luoluo, W Lifeng, M ZHANG… - Chinese Journal of …, 2023 - search.ebscohost.com
Background and objective In recent years, immunotherapy represented by programmed cell
death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunosuppressants has greatly …
death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunosuppressants has greatly …
Relationship between PD-L1 protein expression and 18F-FDG PET/CT metabolic markers in non-small cell lung cancer
J Liu, F Zheng, Z Zhu, D Shi - Int J Radiat Med Nucl Med, 2023 - ijrmnm.com
Objective To investigate the relationship between programmed death-ligand 1 (PD-L1)
protein expression in non-small cell lung cancer (NSCLC) tissues and 18 F …
protein expression in non-small cell lung cancer (NSCLC) tissues and 18 F …
PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
X Wu, Y Huang, Q Zhao, L Wang, X Song, Y Li… - EJNMMI research, 2020 - Springer
Background Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-
L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring …
L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring …
Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography …
DJ Hughes, E Josephides, R O'Shea… - European …, 2024 - Springer
Background Programmed death-ligand 1 (PD-L1) expression is a predictive biomarker for
immunotherapy in non-small cell lung cancer (NSCLC). PD-L1 and glucose transporter 1 …
immunotherapy in non-small cell lung cancer (NSCLC). PD-L1 and glucose transporter 1 …
[HTML][HTML] Value of 18F-FDG PET/CT Based on PD-L1 to Predict Outcomes of Immunotherapy in NSCLC
F Xie, M Li, X Jing - Advances in Bioscience and Biotechnology, 2023 - scirp.org
Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein-1 (PD-1) and
its ligand (PD-L1), have changed the treatment history of lung cancer, especially in the field …
its ligand (PD-L1), have changed the treatment history of lung cancer, especially in the field …
Texture Features of 18F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer
T Norikane, M Ishimura, K Mitamura… - Journal of Clinical …, 2024 - mdpi.com
Background: Identifying programmed death-ligand-1 (PD-L1) expression is crucial for
optimizing treatment strategies involving immune checkpoint inhibitors. However, the role of …
optimizing treatment strategies involving immune checkpoint inhibitors. However, the role of …
The correlation between PD-L1 expression and metabolic parameters of 18FDG PET/CT and the prognostic value of PD-L1 in non-small cell lung cancer
X Xu, J Li, Y Yang, S Sang, S Deng - Clinical Imaging, 2022 - Elsevier
Objectives In the present study, we aimed to investigate the relationship between metabolic
parameters of 18 F-fluorodeoxyglucose positron emission computed tomography (18 F-FDG …
parameters of 18 F-fluorodeoxyglucose positron emission computed tomography (18 F-FDG …
Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by 18F-FDG PET/CT Radiomics and Clinicopathological Characteristics
J Li, S Ge, S Sang, C Hu, S Deng - Frontiers in Oncology, 2021 - frontiersin.org
Purpose In the present study, we aimed to evaluate the expression of programmed death-
ligand 1 (PD-L1) in patients with non-small cell lung cancer (NSCLC) by radiomic features of …
ligand 1 (PD-L1) in patients with non-small cell lung cancer (NSCLC) by radiomic features of …
Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics
X Zhao, Y Zhao, J Zhang, Z Zhang, L Liu, X Zhao - EJNMMI research, 2023 - Springer
Background In recent years, immune checkpoint inhibitor (ICI) therapy has greatly changed
the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the …
the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the …